ReviewNature reviews. Urology2021
Late adverse effects and quality of life in survivors of testicular germ cell tumour.
Review in Nature reviews. Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2023Trial
- A Randomized Controlled Trial of Goal-Focused Emotion-Regulation Therapy for Young Adult Survivors of Testicular Cancer: Effects on Salivary and Inflammatory Stress Markers.American journal of men's healthTrial
- Aging-related deficits accumulation and cancer-related outcomes in testicular and prostate cancer: Cross-sectional and longitudinal findings.Social science & medicine (1982) · 2026Article
- Testicular mass frozen section examination: Pathological insights and diagnostic accuracy.Histopathology · 2026Article
- Validation of the Testicular Health Outcomes Report (THOR): a testicular cancer health-related quality of life instrument.BJU international · 2026Article
- Cisplatin - induced peripheral neuropathy and biomarkers of gut microbial translocation in testicular germ cell tumor survivors.Frontiers in immunology · 2026Article
- TNFSF10: a promising prognostic biomarker and therapeutic target for immunotherapy in testicular germ cell tumors.Frontiers in immunology · 2026Article
- Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours.Andrology · 2026Article
- Systematic Review and Meta-Analysis of the Management of Relapsed Germ Cell Tumours Following Cisplatin-Based Chemotherapy.Oncology and therapy · 2025Review
- Changes in methylation associated with development of metabolic syndrome in testicular cancer patients treated with cisplatin chemotherapy.Scientific reports · 2025Article
- Single-cell analysis unravels divergent gene signatures shaping seminoma stemness and metastasis.Cell death discovery · 2025Article
- ASPM Induces Radiotherapy Resistance by Disrupting Microtubule Stability Leading to Chromosome Malsegregation in Non-Small Cell Lung Cancer.Exploration (Beijing, China) · 2025Article
- Target Mapping in Cancer: Ligandable Protein Pockets on 3D OncoPPI Networks.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Oncological microdissection testicular sperm extraction (Onco-microTESE) outcomes for fertility preservation of patients with testicular cancer with azoospermia or severe oligoasthenoteratozoospermia.BJU international · 2025Article
- Cardiovascular toxicity in testicular germ cell tumor survivors.Frontiers in oncology · 2025Review
- Immune cell profiling of peripheral blood in long-term testicular germ cell tumor survivors.Frontiers in immunology · 2025Article
- Global burden and trends of testicular cancer in adolescents and young adults from 1990 to 2021, with predictions to 2035.Scientific reports · 2024Article
- Young adult Latino testicular cancer survivors: a pilot study of Goal-focused Emotion regulation Therapy (GET).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired systolic function and tissue alterations.European radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, ~95% of patients with testicular germ cell tumour (TGCT) are cured, resulting in an increasing number of TGCT survivors. Although cured, these men face potential late adverse effects and reduced quality of life. Survivors face a twofold increased risk of second malignant neoplasms after chemotherapy and radiotherapy, with evidence of dose-dependent associations. For survivors managed with surveillance or treated with radiotherapy, the risk of cardiovascular disease (CVD) is comparable to the risk in the general population, whereas treatment with chemotherapy increases the risk of life-threatening CVD, especially during treatment and after 10 years of follow-up. Other adverse effects are organ-related toxicities such as neuropathy and ototoxicity. Pulmonary and renal impairment in patients with TGCT treated with chemotherapy is limited. Survivors of TGCT might experience psychosocial distress including anxiety disorders, fear of cancer recurrence and TGCT-specific issues, such as sexual dysfunction. Late adverse effects can be avoided in most patients with stage I disease if followed on a surveillance programme. However, patients with disseminated disease can experience toxicities associated with radiotherapy and chemotherapy, and/or adverse effects related to surgery for residual disease. The severity of adverse effects increases with dose of both chemotherapy and radiotherapy. This Review discusses the most recent data concerning the late adverse effects of today's standard treatments for TGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.